SCHEMBL390952

SCHEMBL390952

[c]1nc2scnc2s1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1661978 0.71
SCHEMBL622901 0.71
SCHEMBL6022371 0.63
SCHEMBL971983 0.60
SCHEMBL234253 0.59
SCHEMBL269976 0.59
SCHEMBL1328659 0.57
SCHEMBL2003061 0.57
SCHEMBL253701 0.57
SCHEMBL20523294 0.56

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 546 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12018030-B2 Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors VALO HEALTH, INC. (US) 2024-06-25 US claimed
US-11739071-B2 Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors VALO HEALTH, INC. (US) 2023-08-29 US claimed
US-20210130321-A1 QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS VALO HEALTH, INC. 2021-05-06 US claimed
US-10889592-B2 Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors VALO EARLY DISCOVERY, INC. (US) 2021-01-12 US claimed
US-12043623-B2 Purinones as ubiquitin-specific protease 1 inhibitors FORMA THERAPEUTICS, INC. (US) 2024-07-23 US disclosed
US-20240239785-A1 SUBSTITUTED 2-(2,6-DIOXOPIPERIDIN-3-YL)-5-(1-PIPERIDIN-4-YL)ISOINDOLINE-1,3-DIONE DERIVATIVES AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. 2024-07-18 US disclosed
US-12030862-B2 Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease PETRA PHARMA CORPORATION (US) 2024-07-09 US disclosed
WO-2024137548-A2 INHIBITORS OF JAK2 Llydaw Therapeutics, Inc. (US) 2024-06-27 WO disclosed
US-20240208960-A1 AMINOTHIAZOLE COMPOUNDS AS C-KIT INHIBITORS TAKEDA PHARMACEUTICALS U.S.A., INC. 2024-06-27 US disclosed
US-12018030-B2 Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors VALO HEALTH, INC. (US) 2024-06-25 US disclosed
US-20240199616-A1 BICYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2024-06-20 US disclosed
WO-2024129395-A1 BTK INHIBITORS GWYNANT THERAPEUTICS, INC. (US) 2024-06-20 WO disclosed
WO-2015074081-A1 BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS BAIR KENNETH W (US) 2015-05-21 WO disclosed
WO-2015074064-A2 TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS BAIR KENNETH W (US) 2015-05-21 WO disclosed
EP-2573833-A1 Organic semiconductors, their manufacture and semiconductor devices comprising them BASF SE (DE) 2013-03-27 EP disclosed
EP-1961052-B1 ORGANIC SEMICONDUCTORS AND THEIR MANUFACTURE BASF SE (DE) 2013-03-06 EP disclosed
US-8101776-B2 Organic semiconductors and their manufacture BASF SE (DE) 2012-01-24 US disclosed
US-20090299070-A1 Organic Semiconductors and Their Manufacture CLAP CO., LTD. (KR) 2009-12-03 US disclosed
EP-1961052-A1 ORGANIC SEMICONDUCTORS AND THEIR MANUFACTURE Ciba Specialty Chemicals Holding Inc. (CH) 2008-08-27 EP disclosed
WO-2007068618-A1 ORGANIC SEMICONDUCTORS AND THEIR MANUFACTURE CIBA HOLDING INC. (CH) 2007-06-21 WO disclosed